Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sutetinib malate
- Development stage
- Phase 3
- Lead developer
- Teligene
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sutetinib malate is an orally bioavailable, mutant-selective, irreversible small molecule inhibitor of the epidermal growth factor receptor (EGFR). It is designed to target and inhibit uncommon, non-resistant EGFR mutations, such as L861Q, G719X, and S768I, while sparing wild-type EGFR to minimize off-target toxicities. Sutetinib malate is being developed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring these rare mutations. It was co-developed by Suzhou Teligene and Jiangsu Suzhong Pharmaceutical Group, and has received breakthrough therapy designation from China's National Medical Products Administration (NMPA).
- Other names
- sutetinibsutetinib (maleate)sutetinib maleate
02
Targets
Beyond the preview
Go deeper on sutetinib malate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sutetinib malate.